1 / 25

Psych 181: Dr. Anagnostaras Lec 10: Marijuana

Psych 181: Dr. Anagnostaras Lec 10: Marijuana. Westerm world find bioactiv. 1st archaeological evidence of hemp use. Ritual use in India. Use semi-legal in CA/AZ. Medical use in China. Hashish use in Arab world. 8000 BC. 2700 BC. 2000 BC. 1000 AD. 1850s. 1996.

kaycee
Download Presentation

Psych 181: Dr. Anagnostaras Lec 10: Marijuana

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Psych 181: Dr. Anagnostaras Lec 10: Marijuana

  2. Westerm world find bioactiv. 1st archaeological evidenceof hemp use Ritual usein India Use semi-legal in CA/AZ Medical usein China Hashish use inArab world 8000 BC 2700 BC 2000 BC 1000 AD 1850s 1996 Marijuana and cannabinoids Cannabis sativa, hempOne of earliest non-food plants cultivated • fiber for rope, seeds for oil and birdseed from Childers & Breivogel (1998)

  3. Marijuana and cannabinoids Cannabinoids • pharmacologically active compounds • over 60 (delta-9-tetrahydrocannabinol (9-THC), 8-THC, cannabinol, etc.)

  4. Forms and preparations Marijuana • mixture of leaves, stems, tops • 1960’s: 1-3% THC; 1990’s: up to 8-10% “Bubble Gum” “Big Bud” “Dutch Northern Lights”

  5. Forms and preparations Hashish • dried resin from top of female plant • THC usually 2-5%, but up to 15% Hash Oil • organic extractionfrom hashish • THC usually ~ 10-20%up to 70%

  6. Synthetic cannabinoids • Developed for research • Some very potent

  7. History • Second only toalcohol & tobacco

  8. History 1960

  9. Pharmacokinetics Absorption • very lipid soluble • good absorption if smoked (20-37%) • rapid peak THC Administration Blood levels 17.2

  10. Pharmacokinetics Absorption • slow absorption with oral THC Administration 17.4 Blood levels Rated “high” 17.2

  11. Metabolism and clearance • rapid initial drop due to redistribution to fats • slower metabolism in liver • metabolites may persist for a week Major biolgically active compound may be metabolite 1. Primary metabolic product of 9-THC (11-OH-9-THC) is more potent than 9-THC 2. Delay between peak plasma levels and “high”

  12. Effects on behavior Low - moderate doses • disinhibition, relaxation, drowsiness • feeling of well being, exhileration, euphoria • sensory - perceptual changes • recent memory impairment • balance/stability impaired • decreased muscle strength, small tremor • poor on complex motor tasks (e.g., driving)

  13. Effects on behavior Psychomotor performance Performance decrement (s) 17.5

  14. Effects on behavior High doses • pseudohallucinations • synesthesias • impaired judgement, reaction time • pronounced motor impairment • increasingly disorganized thoughts, confusion, paranoia, agitation Not lethal even at very high doses

  15. Repeated administration Tolerance 3H-CP-55,940 Binding Control Chronic THC 17.9

  16. Repeated administration Long-term effects • Amotivational syndrome?

  17. Potential medical uses • Glaucoma (increased intraocular pressure) • Antiemetic (reduce nausea and vomiting) • Anticonvulsant • Enhance appetite (e.g., AIDS patients) • Analgesic • THC versus marijuana controversy?

  18. Mechanisms of action Nonspecific? • e.g., membrane fluidity changes Specific?is there a cannabinoid receptor? • small doses effective • effects of d and l isomers different • marked structure-function effects • inhibits cAMP formation via G protein (1986)

  19. Mechanisms of action Is there a cannabinoid receptor? Development of synthetic cannabinoids • 9-THC binds weakly and not full agonist • CP and WIN series of compounds and antagonists (1986-1990s) • first binding experiments (1988) • first localization (1990) • CB-1 receptor cloned (1990) • CB-2 cloned (1993)

  20. Cannabinoid receptor [3H]CP-55,940 Binding 17.8

  21. Cannabinoid receptor Receptor localization • conserved across mammalian species • similar to cAMP distribution • binding inhibitedby cAMP analogues • both CB-1 and CB-2 (peripheral) receptors areG protein coupled • receptor density very high,rivalling amino acid receptors

  22. Endogenous cannabinoids Anandamide • from Sanskrit for “bliss” • arachidonic acid derivative (1992) • similar actions to cannabinoids • inhibit cAMP via cannabinoid receptor • inhibit binding of cannabinoids • only partial agonist at CB-1 • decrease motor activity • antinociceptive effects

  23. Endogenous cannabinoids Others 2-arachidonyl glycerol • full agonist at CB-1 and in brain in higher conc. than anandamide • additional unidentified compounds have been found

  24. Locus of actions Relationship between action & sites of action not known Speculation: • memory effects - hippocampus • reward - mesostriatal DA system • motor activity - basal ganglia, cerebellum • analgesic effects - spinal cord and in peripheral tissue (endogenous compounds effective via non-opiate mechanism)

  25. Actions on DA systems % change in accumbens DA

More Related